246 related articles for article (PubMed ID: 32473921)
1. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
Frigerio M
Int J Cardiol; 2020 Oct; 316():285-286. PubMed ID: 32473921
[No Abstract] [Full Text] [Related]
2. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
Hor CP; Hussin N; Nalliah S; Ooi WT; Tang XY; Zachariah S; Jugindar Singh GPS; Abdul Rani R; Perumal K; Cheah WK
J Infect; 2020 Aug; 81(2):e117-e119. PubMed ID: 32474031
[No Abstract] [Full Text] [Related]
3. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
Bonow RO; Hernandez AF; Turakhia M
JAMA Cardiol; 2020 Sep; 5(9):986-987. PubMed ID: 32936259
[No Abstract] [Full Text] [Related]
4. Hydroxychloroquine and azithromycin as a treatment of COVID-19.
Fanin A; Calegari J; Beverina A; Tiraboschi S;
Intern Emerg Med; 2020 Aug; 15(5):841-843. PubMed ID: 32474851
[No Abstract] [Full Text] [Related]
5. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
Popescu CP; Fischer PR
Travel Med Infect Dis; 2020; 35():101764. PubMed ID: 32485391
[No Abstract] [Full Text] [Related]
6. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
Lebeaux D; Revest M
Travel Med Infect Dis; 2020; 36():101819. PubMed ID: 32629139
[No Abstract] [Full Text] [Related]
7. Flexibilization of Science, Cognitive Biases, and the COVID-19 Pandemic.
Oliveira J E Silva L; Vidor MV; Zarpellon de Araújo V; Bellolio F
Mayo Clin Proc; 2020 Sep; 95(9):1842-1844. PubMed ID: 32861327
[No Abstract] [Full Text] [Related]
8. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
Parra-Lara LG; Martínez-Arboleda JJ; Rosso F
J Glob Antimicrob Resist; 2020 Sep; 22():680-684. PubMed ID: 32622008
[TBL] [Abstract][Full Text] [Related]
9. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
10. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Funck-Brentano C; Salem JE; Nguyen LS; Drici MD; Roden DM
Arch Cardiovasc Dis; 2020 May; 113(5):367-368. PubMed ID: 32331979
[No Abstract] [Full Text] [Related]
11. Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs.
Zampieri FG
Ann Am Thorac Soc; 2020 Aug; 17(8):937-938. PubMed ID: 32735169
[No Abstract] [Full Text] [Related]
12. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
13. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.
Pothen L; Yildiz H; De Greef J; Penaloza A; Beauloye C; Belkhir L; Yombi JC
Travel Med Infect Dis; 2020; 36():101788. PubMed ID: 32540396
[No Abstract] [Full Text] [Related]
14. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
Bonny A; Talle MA; Ngantcha M; Tayebjee MH
Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105
[No Abstract] [Full Text] [Related]
15. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
Rosendaal FR
Int J Antimicrob Agents; 2020 Jul; 56(1):106063. PubMed ID: 32674928
[No Abstract] [Full Text] [Related]
16. [Not Available].
Farfán-López M; Espinoza-Culupú A
Rev Peru Med Exp Salud Publica; 2020; 37(2):383-384. PubMed ID: 32876237
[No Abstract] [Full Text] [Related]
17. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M
JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266
[TBL] [Abstract][Full Text] [Related]
18. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".
Atkinson JG
Int J Infect Dis; 2020 Oct; 99():37. PubMed ID: 32738492
[No Abstract] [Full Text] [Related]
19. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.
Malviya A
Int J Infect Dis; 2020 Oct; 99():310-311. PubMed ID: 32738490
[No Abstract] [Full Text] [Related]
20. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).
Dar SA; Wahid M; Haque S; Almalki SS; Akhter N
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):7923-7924. PubMed ID: 32767316
[No Abstract] [Full Text] [Related]
[Next] [New Search]